Revisiting oral fluoropyrimidine with cetuximab in metastatic colorectal cancer: Real-world data in Chinese population  

作　　者：Ka-On Lam Man-Chi Fu Kin-Sang Lau Kam-Mo Lam Cheuk-Wai Choi Wan-Hang Chiu Cheng-Man Yuen Lai-Han Kwok Fong-Kit Tam Wing-Lok Chan Sum-Yin Chan Pui-Ying Ho To-Wai Leung Ho-Fun Lee 

机构地区：[1]Department of Clinical Oncology,LKS Faculty of Medicine,The University of Hong Kong,Hong Kong,China [2]Department of Clinical Oncology,Queen Mary Hospital,Hong Kong,China [3]Clinical Oncology Centre,The University of Hong Kong-Shenzhen Hospital,Shenzhen 518053,Guangdong Province,China [4]Department of Pharmacy,Queen Mary Hospital,Hong Kong,China [5]Department of Diagnostic Radiology,LKS Faculty of Medicine,The University of Hong Kong,Hong Kong,China

出　　处：《World Journal of Gastrointestinal Oncology》2019年第11期1031-1042,共12页世界胃肠肿瘤学杂志（英文版）（电子版）

摘　　要：BACKGROUND Cetuximab in combination with oral fluoropyrimidine(FP)remains controversial in metastatic colorectal cancer(mCRC).In view of the regional variation in the tolerability of FP,we conducted a retrospective analysis to compare oral FP with infusional FP in combination with cetuximab in Chinese population.AIM To compare the efficacy and safety profile of cetuximab in combination with oral FP and infusional FP in Chinese population in the real-world setting.METHODS A retrospective cohort study was done to analyse consecutive patients with Kras wild-type mCRC who received first-line treatment with cetuximab and FP-based chemotherapy in our unit from January 2010 to December 2015.Ninety-five eligible patients were included.The median follow-up of our cohort was 65.0 mo.RESULTS The median progression-free survival(mPFS)and median overall survival(mOS)of the entire cohort were 9.66 mo(95%CI:7.72–12.5)and 25.8 mo(95%CI:18.7–35.6),respectively.Between oral FP and infusional FP,there was no statistical significant difference in the mPFS[9.79 mo(95%CI:7.49–12.7)vs 9.63 mo(95%CI:6.34–13.4);P=0.72]and mOS[25.8 mo(95%CI:15.2–35.6)vs 26.3 mo(95%CI:18.7–41.2);P=0.63].Grade 3 or above adverse events were reported in 28.4%of patients,being similar with oral and infusional FP,and included 10.5%of neutropenia and 2.1%of diarrhoea events.CONCLUSION The current analysis demonstrates comparable efficacy and safety profiles of cetuximab in combination with oral and infusional FP in Chinese population.The results expand treatment options for Chinese patients and invite revision of existing treatment guidelines to incorporate oral FP-based chemotherapy plus cetuximab.BACKGROUND Cetuximab in combination with oral fluoropyrimidine(FP) remains controversial in metastatic colorectal cancer(mCRC).In view of the regional variation in the tolerability of FP, we conducted a retrospective analysis to compare oral FP with infusional FP in combination with cetuximab in Chinese population.AIM To compare the efficacy and safety profile of cetuximab in combination with oral FP and infusional FP in Chinese population in the real-world setting.METHODS A retrospective cohort study was done to analyse consecutive patients with Kras wild-type mCRC who received first-line treatment with cetuximab and FP-based chemotherapy in our unit from January 2010 to December 2015.Ninety-five eligible patients were included.The median follow-up of our cohort was 65.0 mo.RESULTS The median progression-free survival(mPFS) and median overall survival(mOS)of the entire cohort were 9.66 mo(95%CI: 7.72–12.5) and 25.8 mo(95%CI:18.7–35.6), respectively.Between oral FP and infusional FP, there was no statistical significant difference in the mPFS [9.79 mo(95%CI: 7.49–12.7) vs 9.63 mo(95%CI: 6.34–13.4); P = 0.72] and mOS [25.8 mo(95%CI: 15.2–35.6) vs 26.3 mo(95%CI: 18.7–41.2); P = 0.63].Grade 3 or above adverse events were reported in28.4% of patients, being similar with oral and infusional FP, and included 10.5%of neutropenia and 2.1% of diarrhoea events.CONCLUSION The current analysis demonstrates comparable efficacy and safety profiles of cetuximab in combination with oral and infusional FP in Chinese population.The results expand treatment options for Chinese patients and invite revision of existing treatment guidelines to incorporate oral FP-based chemotherapy plus cetuximab.

关 键 词：CAPECITABINE 5-FLUOROURACIL CETUXIMAB METASTATIC COLORECTAL cancer Chinese 

分 类 号：R73[医药卫生—肿瘤]